Free Trial

Emily Field Analyst Performance

Director, Head of European Pharmaceuticals Equity Research at Barclays

Emily Field is a stock analyst at Barclays in the medical sector, covering 11 publicly traded companies. Over the past year, Emily Field has issued 17 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Emily Field's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emily Field's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
19 Last 4 Years
Buy Recommendations
47.37% 9 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy5.3%1 ratings
Buy42.1%8 ratings
Hold42.1%8 ratings
Sell10.5%2 ratings

Out of 19 total stock ratings issued by Emily Field at Barclays, the majority (42.1%) have been Buy recommendations, followed by 42.1% Hold, 10.5% Sell, and 5.3% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
54.5% of companies on NYSE
6 companies
NASDAQ
36.4% of companies on NASDAQ
4 companies
OTCMKTS
9.1% of companies on OTCMKTS
1 company

Emily Field, an analyst at Barclays, currently covers 11 companies listed on NYSE, NASDAQ and OTCMKTS, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
11 companies
100.0%

Emily Field of Barclays specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
5 companies
45.5%
MED - BIOMED/GENE
5 companies
45.5%
PHARMACEUTICAL PREPARATIONS
1 company
9.1%

Emily Field's Ratings History at Barclays

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
5/4/2026Boost Price Target$968.06$1,400.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/20/2026Initiated Coverage$151.12$155.00Equal Weight
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2/20/2026Initiated Coverage$121.83$140.00Overweight
Amgen Inc. stock logo
AMGN
Amgen
2/20/2026Initiated Coverage$373.21$350.00Equal Weight
Biogen Inc. stock logo
BIIB
Biogen
2/19/2026Initiated Coverage$192.08$185.00Equal Weight
Pfizer Inc. stock logo
PFE
Pfizer
2/19/2026Initiated Coverage$26.87$25.00Underweight
AbbVie Inc. stock logo
ABBV
AbbVie
2/19/2026Initiated Coverage$224.13$275.00Overweight
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2/19/2026Initiated Coverage$60.32$75.00Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2/19/2026Initiated Coverage$1,023.10$1,350.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
2/19/2026Initiated Coverage$224.94$275.00Overweight
Amgen Inc. stock logo
AMGN
Amgen
2/19/2026Upgrade$374.75Hold
Biogen Inc. stock logo
BIIB
Biogen
2/19/2026Upgrade$192.03Hold
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2/19/2026Initiated Coverage$60.66$75.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/19/2026Upgrade$151.40Hold
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2/19/2026Initiated Coverage$1,008.47$1,350.00Overweight
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2/19/2026Upgrade$122.05Strong-Buy
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
7/30/2025Reiterated Rating$53.97Equal Weight
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
1/23/2025Reiterated Rating$23.93Underweight